Fluofarma Overview

  • Founded
  • 2003

  • Status
  • Acquired/​Merged

  • Employees
  • 17

  • Latest Deal Type
  • M&A

Fluofarma General Information


Provider of content analysis technologies to perform and develop cell-based assays. The company offers following services including assay development, cell-based screening, drug profiling, predictive toxicology, biomarker analysis in blood and tissues.

Contact Information

Ownership Status
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Other Industries
Laboratory Services (Healthcare)
Monitoring Equipment
Primary Office
  • 2 rue Robert Escarpit
  • 33600 Pessac
  • France

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Fluofarma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 10-Dec-2015 Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Fluofarma’s complete valuation and funding history, request access »

Fluofarma Patents

Fluofarma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20150131887-A1 System and method to visualize and analyze data from image-based cellular assays or high content screening Inactive 15-Apr-2011 000000000

Fluofarma Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Fluofarma Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Incubateur Régional d'Aquitaine Accelerator/Incubator 000 0000 000000 0
To view Fluofarma’s complete investors history, request access »